Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Spectranetics Corp Issues FY 2013 Revenue And EBITDA Guidance Above Analysts' Estimates; Issues FY 2013 EPS And Net Income Guidance Below Analysts' Estimates


Thursday, 21 Feb 2013 06:00am EST 

Spectranetics Corp announced that for fiscal 2013, it expects net revenue to be in the range of $153.0-$155.5 million, an increase of 9%-11% from 2012. Net income for fiscal 2013 is projected to be in the range of $0.0-$0.5 million, or $0.00-$0.01 per diluted share (EPS), including the impact of the Medical Device Tax which is estimated to be approximately $2.5 million for 2013. Earnings before interest, taxes, depreciation, amortization, special items and the medical device tax (Adjusted EBITDA) is anticipated to be in the range of $13.5-$14.5 million in fiscal 2013, compared with Adjusted EBITDA of $13.1 million in 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $152 million, net profit of $1.81 million, EPS of $0.09 and EBITDA of $9.64 million for fiscal 2013. 

Company Quote

33.89
-0.12 -0.35%
11:01am EST